Literature DB >> 10845409

Pharmacological properties of parenteral cephalosporins: rationale for ambulatory use.

E Strehl1, F Kees.   

Abstract

Parenteral cephalosporins are among the most frequently used antibiotics in hospital therapy. They are characterised by an extended spectrum of activity against gram-positive and gram-negative bacteria, and some also have good activity against anaerobes. They kill proliferating bacterial cells rapidly, and generally show only a low tendency to select resistant mutants. However, there are cephalosporin compounds which induce cephalosporinases very rapidly in certain microorganisms. Together with other beta-lactam antibiotics, parenteral cephalosporins interfere with bacterial cell wall synthesis by inhibiting peptidoglycan cross-linkage. Because of this specific target, they are nontoxic to mammalian cells, and have a very favourable adverse effect profile. The chemical stability of parenteral cephalosporins in aqueous solution is good. After intravenous injection, high concentrations of these agents are achieved in serum and tissue. Most cephalosporins are eliminated unchanged via the kidney, with a half-life of 1 to 2 hours. But there are also derivatives with a serum half-life of more than 2 and up to 8 hours, allowing 12- or 24-hour dosage intervals. Because of their reliable efficacy and low risk of adverse effects, the parenteral cephalosporins offer a high degree of tolerability even in the setting of outpatient antibiotic therapy. In particular, the derivatives of the third generation are characterised by unique pharmacological properties.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10845409     DOI: 10.2165/00003495-200059003-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  37 in total

Review 1.  Combination antimicrobial therapy for bacterial infections. Guidelines for the clinician.

Authors:  M J Rybak; B J McGrath
Journal:  Drugs       Date:  1996-09       Impact factor: 9.546

Review 2.  In vitro antibacterial effects of cephalosporins.

Authors:  J D Williams; F Moosdeen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

3.  Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study.

Authors:  P Francioli; W Ruch; D Stamboulian
Journal:  Clin Infect Dis       Date:  1995-12       Impact factor: 9.079

Review 4.  Mechanisms of resistance to cephalosporin antibiotics.

Authors:  D M Livermore
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 5.  Pharmacokinetic properties of the cephalosporins.

Authors:  T Bergan
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 6.  Considerations in dosage selection for third generation cephalosporins.

Authors:  J H Yuk-Choi; C H Nightingale; T W Williams
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

7.  Treatment of skin and soft-tissue infections utilizing an outpatient parenteral drug delivery device: a multicenter trial. HIAT Study Group.

Authors:  D M Poretz
Journal:  Am J Med       Date:  1994-08-15       Impact factor: 4.965

Review 8.  Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.

Authors:  W A Craig
Journal:  Diagn Microbiol Infect Dis       Date:  1995 May-Jun       Impact factor: 2.803

Review 9.  Third-generation cephalosporins.

Authors:  N C Klein; B A Cunha
Journal:  Med Clin North Am       Date:  1995-07       Impact factor: 5.456

Review 10.  Parenteral aminoglycoside therapy. Selection, administration and monitoring.

Authors:  C R Kumana; K Y Yuen
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.